Armata Pharmaceuticals, Inc. 8-K

What Happened
Armata Pharmaceuticals, Inc. announced its financial results for the three months and full fiscal year ended December 31, 2025, and furnished a press release dated March 25, 2026 as Exhibit 99.1 to a Form 8-K filed the same day. The Form 8-K (Item 2.02) reports the results of operations and financial condition; the filing was signed by David House, Senior Vice President, Finance and Principal Financial Officer.

Key Details

• Item reported: 2.02 — Results of Operations and Financial Condition (press release furnished).
• Period covered: three months and full fiscal year ended December 31, 2025.
• Exhibit: 99.1 — Press Release dated March 25, 2026 (also included Cover Page Inline XBRL as Exhibit 104).
• Filing signed by: David House, SVP Finance and Principal Financial Officer, dated March 25, 2026.

Why It Matters
Earnings and year‑end results provide updated information on Armata’s revenue, expenses, cash position and operational progress—key inputs for evaluating the company’s financial health and near‑term outlook. Retail investors should review the March 25, 2026 press release (Exhibit 99.1) for the specific revenue, profit/loss, cash runway and any management commentary or guidance disclosed, as those details will drive investor reaction and inform investment decisions.